title: Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.
authors.affiliation: Institute for Lung Health, Glenfield Hospital, Leicester, United Kingdom; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.
authors.forename: Pranabashis
authors.initials: P
authors.lastname: Haldar
authors.affiliation: Institute for Lung Health, Glenfield Hospital, Leicester, United Kingdom; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.
authors.forename: Christopher E
authors.initials: CE
authors.lastname: Brightling
authors.affiliation: Institute for Lung Health, Glenfield Hospital, Leicester, United Kingdom.
authors.forename: Amisha
authors.initials: A
authors.lastname: Singapuri
authors.affiliation: Institute for Lung Health, Glenfield Hospital, Leicester, United Kingdom.
authors.forename: Beverley
authors.initials: B
authors.lastname: Hargadon
authors.affiliation: Institute for Lung Health, Glenfield Hospital, Leicester, United Kingdom; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.
authors.forename: Sumit
authors.initials: S
authors.lastname: Gupta
authors.affiliation: Institute for Lung Health, Glenfield Hospital, Leicester, United Kingdom.
authors.forename: William
authors.initials: W
authors.lastname: Monteiro
authors.affiliation: Institute for Lung Health, Glenfield Hospital, Leicester, United Kingdom; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.
authors.forename: Peter
authors.initials: P
authors.lastname: Bradding
authors.affiliation: Institute for Lung Health, Glenfield Hospital, Leicester, United Kingdom.
authors.forename: Ruth H
authors.initials: RH
authors.lastname: Green
authors.affiliation: Institute for Lung Health, Glenfield Hospital, Leicester, United Kingdom; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, United Kingdom.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Wardlaw
authors.affiliation: Respiratory Therapeutic Area Unit, R&D, GlaxoSmithKline, Research Triangle Park, NC.
authors.forename: Hector
authors.initials: H
authors.lastname: Ortega
authors.affiliation: Respiratory Medicine Unit, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Headington, Oxford, United Kingdom. Electronic address: ian.pavord@ndm.ox.ac.uk.
authors.forename: Ian D
authors.initials: ID
authors.lastname: Pavord
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D015848:Interleukin-5 / Q000037:antagonists & inhibitors*; D011446:Prospective Studies; D011657:Pulmonary Eosinophilia / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015848:Interleukin-5; C434107:mepolizumab